COVID-19 and Pembrolizumab-Induced Secondary Hemophagocytic Lymphohistiocytosis: a Case Report.

Luis Ramos-RupertoCarmen Busca-ArenzanaJuan ValdiviesoEduardo López-GranadosÁngel Robles-Marhuenda

Published in: SN comprehensive clinical medicine (2021)

Our case highlights SARS-CoV-2 and pembrolizumab as trigger of secondary hemophagocytic lymphohistiocytosis. Although it is a rare complication, it must be suspected in order to start specific treatment. In this context, intravenous immunoglobulins could be a therapeutic option.

Keyphrases

sars cov
respiratory syndrome coronavirus
advanced non small cell lung cancer
coronavirus disease
high glucose
diabetic rats
pulmonary embolism
drug induced
oxidative stress
low dose
epidermal growth factor receptor